Ocuphire Pharma
As of the edition of 20 October 2026, Ocuphire Pharma runs 2 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Ocuphire Pharma was renamed in 2024.
The records place 2 company names in this family.
- Ocuphire Pharma, Inc.: renamed in 2024
- Opus Genetics, Inc: acquired in 2024; successor Ocuphire Pharma, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Phentolamine | none listed | 3 |
A route B row is one company at one target.
Where its trials are
- Eye: 1 trials led
- Heart and blood vessels: 1 trials led
- Hormones: 1 trials led